Guideline directed-medical therapy for heart failure within 3 months post LVAD implant and rehospitalization
Authors:
- Ernesto Ruiz-DuqueERErnesto Ruiz-Duque
- Chris KourekCKChris Kourek
- Paulino AlvarezPAPaulino Alvarez
- Ibrahim MortadaIMIbrahim Mortada
- Alexandros BriasoulisABAlexandros Briasoulis
Open Access
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Factors Associated with the Use of Guideline-Directed Medical Therapy in Patients with Left Ventricular Assist DeviceEuropean Journal of Heart Failure, 2025
- SGLT-2 inhibitors as novel treatments of multiple organ fibrosisHeliyon, 2024
- “Durable left ventricular assist devices as a bridge to transplantation in The Old and The New World”The Journal of Heart and Lung Transplantation, 2024
- Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection FractionDrugs, 2023
- The good, the bad, the ugly: Optimal left ventricular assist device duration in bridge to transplantationJTCVS Open, 2021
- Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist DevicesJAMA Cardiology, 2020
- Left ventricular assist device as destination therapy for end stage heart failureCurrent Opinion in Cardiology, 2018
- Neurohormonal activation in heart failure with reduced ejection fractionNature Reviews Cardiology, 2016
- Hospital Readmissions After Continuous-Flow Left Ventricular Assist Device Implantation: Incidence, Causes, and Cost AnalysisThe Annals of Thoracic Surgery, 2015
- Novel Therapeutic Approaches to Preserve the Right VentricleCurrent Heart Failure Reports, 2012